• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

工程毒液的毒素中和抗体片段及其治疗潜力。

Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

机构信息

Muséum National d'Histoire Naturelle, UMR MNHN-CNRS 7245, 12 rue Buffon, 75231 Paris Cedex 05, France.

Université de Tours-INRA, UMR 1282, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours Cedex, France.

出版信息

Toxins (Basel). 2014 Aug 21;6(8):2541-67. doi: 10.3390/toxins6082541.

DOI:10.3390/toxins6082541
PMID:25153256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4147596/
Abstract

Serum therapy remains the only specific treatment against envenoming, but anti-venoms are still prepared by fragmentation of polyclonal antibodies isolated from hyper-immunized horse serum. Most of these anti-venoms are considered to be efficient, but their production is tedious, and their use may be associated with adverse effects. Recombinant antibodies and smaller functional units are now emerging as credible alternatives and constitute a source of still unexploited biomolecules capable of neutralizing venoms. This review will be a walk through the technologies that have recently been applied leading to novel antibody formats with better properties in terms of homogeneity, specific activity and possible safety.

摘要

血清疗法仍然是唯一针对中毒的特异性治疗方法,但抗毒液仍然是通过从高度免疫的马血清中分离的多克隆抗体进行片段化制备的。大多数这些抗毒液被认为是有效的,但它们的生产繁琐,并且其使用可能与不良反应有关。重组抗体和更小的功能单位现在作为可信的替代品出现,并且是能够中和毒液的仍然未被开发的生物分子的来源。这篇综述将带您了解最近应用的技术,这些技术导致了新型抗体形式的出现,这些新型抗体在均一性、特异性活性和可能的安全性方面具有更好的特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/42b0bd0db1f0/toxins-06-02541-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/7ad649691b50/toxins-06-02541-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/7ce9ceb63596/toxins-06-02541-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/709e9f73b450/toxins-06-02541-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/da0a59044888/toxins-06-02541-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/10287f3924f6/toxins-06-02541-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/0f55b893b338/toxins-06-02541-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/42b0bd0db1f0/toxins-06-02541-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/7ad649691b50/toxins-06-02541-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/7ce9ceb63596/toxins-06-02541-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/709e9f73b450/toxins-06-02541-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/da0a59044888/toxins-06-02541-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/10287f3924f6/toxins-06-02541-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/0f55b893b338/toxins-06-02541-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/512f/4147596/42b0bd0db1f0/toxins-06-02541-g007.jpg

相似文献

1
Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.工程毒液的毒素中和抗体片段及其治疗潜力。
Toxins (Basel). 2014 Aug 21;6(8):2541-67. doi: 10.3390/toxins6082541.
2
[Recombinant antibodies: towards a new generation of antivenoms?].[重组抗体:迈向新一代抗蛇毒血清?]
J Soc Biol. 2006;200(4):345-54. doi: 10.1051/jbio:2006038.
3
Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2.定向进化、噬菌体展示及进化突变体的组合:恢复抗蝎毒素Cn2的中和性单克隆抗体BCF2的单链抗体片段(scFv)版本中和特性的策略
J Mol Biol. 2005 Mar 11;346(5):1287-97. doi: 10.1016/j.jmb.2004.12.060. Epub 2005 Jan 16.
4
Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism.在蜘蛛毒中毒中产生具有毒素中和潜力的重组抗体片段。
Immunol Lett. 2016 Aug;176:90-6. doi: 10.1016/j.imlet.2016.05.019. Epub 2016 Jun 7.
5
Pros and cons of different therapeutic antibody formats for recombinant antivenom development.用于重组抗蛇毒血清开发的不同治疗性抗体形式的利弊。
Toxicon. 2018 May;146:151-175. doi: 10.1016/j.toxicon.2018.03.004. Epub 2018 Mar 10.
6
Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims.生物合成多克隆抗蛇毒血清(BOA)治疗蛇伤和下一代蛇伤治疗方法。
Toxins (Basel). 2018 Dec 13;10(12):534. doi: 10.3390/toxins10120534.
7
Nanobodies as novel therapeutic agents in envenomation.纳米抗体作为新型毒液中毒治疗剂。
Biochim Biophys Acta Gen Subj. 2018 Dec;1862(12):2955-2965. doi: 10.1016/j.bbagen.2018.08.019. Epub 2018 Aug 30.
8
Immunological aspects of scorpion toxins: current status and perspectives.蝎子毒素的免疫学方面:现状与展望
Inflamm Allergy Drug Targets. 2011 Oct;10(5):358-68. doi: 10.2174/187152811797200713.
9
Immunotoxicotherapy: successes, disappointments and hopes.免疫毒素疗法:成功、失望与希望
Hum Exp Toxicol. 1997 Oct;16(10):602-8. doi: 10.1177/096032719701601009.
10
Innovative Immunization Strategies for Antivenom Development.创新的抗蛇毒血清开发免疫策略。
Toxins (Basel). 2018 Nov 2;10(11):452. doi: 10.3390/toxins10110452.

引用本文的文献

1
Enhancing the Bothropic Antivenom through a Reverse Antivenomics Approach.通过反向抗蛇毒血清组学方法增强矛头蝮蛇抗蛇毒血清
J Proteome Res. 2025 Feb 7;24(2):881-890. doi: 10.1021/acs.jproteome.4c01028. Epub 2025 Jan 21.
2
Neutralizing anti-diphtheria toxin scFv produced by phage display.噬菌体展示技术制备的抗白喉毒素单链抗体
Biotechnol Lett. 2024 Jun;46(3):385-398. doi: 10.1007/s10529-024-03476-1. Epub 2024 Apr 12.
3
Production of recombinant scorpion antivenoms in E. coli: current state and perspectives.重组蝎类抗蛇毒血清在大肠杆菌中的生产:现状与展望。

本文引用的文献

1
Immunological profile of antivenoms: preclinical analysis of the efficacy of a polyspecific antivenom through antivenomics and neutralization assays.抗蛇毒血清的免疫学特征:通过抗蛇毒血清组学和中和试验对多价抗蛇毒血清疗效进行临床前分析。
J Proteomics. 2014 Jun 13;105:340-50. doi: 10.1016/j.jprot.2014.02.021. Epub 2014 Feb 28.
2
Antibodies to watch in 2014.2014年需关注的抗体。
MAbs. 2014 Jan 1;6(1):5-14. doi: 10.4161/mabs.27333. Epub 2013 Nov 25.
3
Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Appl Microbiol Biotechnol. 2023 Jul;107(13):4133-4152. doi: 10.1007/s00253-023-12578-1. Epub 2023 May 18.
4
Monoclonal-Based Antivenomics Reveals Conserved Neutralizing Epitopes in Type I PLA Molecules from Coral Snakes.基于单克隆抗体的抗蛇毒组学揭示了珊瑚蛇 I 型 PLA 分子中的保守中和表位。
Toxins (Basel). 2022 Dec 26;15(1):15. doi: 10.3390/toxins15010015.
5
Antibodies as Snakebite Antivenoms: Past and Future.抗体在蛇伤抗毒血清中的应用:过去与未来。
Toxins (Basel). 2022 Sep 1;14(9):606. doi: 10.3390/toxins14090606.
6
Crotoxin B: Heterologous Expression, Protein Folding, Immunogenic Properties, and Irregular Presence in Crotalid Venoms.响尾蛇毒素 B:异源表达、蛋白折叠、免疫原性和在响尾蛇毒液中的不规则存在。
Toxins (Basel). 2022 May 31;14(6):382. doi: 10.3390/toxins14060382.
7
Isolation of Polyclonal Single-Chain Fragment Variable (scFv) Antibodies Against Venomous Snakes of Iran and Evaluation of Their Capability in Neutralizing the Venom.伊朗毒蛇多克隆单链可变片段(scFv)抗体的分离及其毒液中和能力评估
Iran J Pharm Res. 2020 Summer;19(3):288-296. doi: 10.22037/ijpr.2019.14400.12358.
8
Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Snake Venom.抗蛇毒出血和肌毒性成分纳米抗体的研制。
Front Immunol. 2020 May 7;11:655. doi: 10.3389/fimmu.2020.00655. eCollection 2020.
9
Innovative Immunization Strategies for Antivenom Development.创新的抗蛇毒血清开发免疫策略。
Toxins (Basel). 2018 Nov 2;10(11):452. doi: 10.3390/toxins10110452.
10
Antivenom Production against and Snake Venoms Using Cross-Linked Chitosan Nanoparticles as an Immunoadjuvant.抗蛇毒血清的制备及交叉链接壳聚糖纳米粒子作为免疫佐剂对抗 和 蛇毒。
Toxins (Basel). 2018 Apr 16;10(4):158. doi: 10.3390/toxins10040158.
工程改造的针对狂犬病病毒糖蛋白 G 的重组三价单链可变片段抗体,具有提高的中和效力。
Mol Immunol. 2014 Feb;57(2):66-73. doi: 10.1016/j.molimm.2013.08.009. Epub 2013 Oct 1.
4
New approaches & technologies of venomics to meet the challenge of human envenoming by snakebites in India.蛇伤致人体中毒的新型 venomomics 方法与技术研究进展及其在印度的挑战应对
Indian J Med Res. 2013;138(1):38-59.
5
Isolation of human monoclonal antibodies from peripheral blood B cells.从外周血 B 细胞中分离人单克隆抗体。
Nat Protoc. 2013 Oct;8(10):1907-15. doi: 10.1038/nprot.2013.117. Epub 2013 Sep 12.
6
Serrumab: a novel human single chain-fragment antibody with multiple scorpion toxin-neutralizing capacities.血清抗体:一种具有多种蝎毒素中和能力的新型人源单链片段抗体。
J Immunotoxicol. 2014 Apr-Jun;11(2):133-40. doi: 10.3109/1547691X.2013.809175. Epub 2013 Sep 3.
7
Safety of intravenous equine F(ab')2: insights following clinical trials involving 1534 recipients of scorpion antivenom.静脉注射马 F(ab')2 的安全性:涉及 1534 名蝎子抗毒液接受者的临床试验后的见解。
Toxicon. 2013 Dec 15;76:386-93. doi: 10.1016/j.toxicon.2013.07.017. Epub 2013 Aug 2.
8
Expression of recombinant antibodies.表达重组抗体。
Front Immunol. 2013 Jul 29;4:217. doi: 10.3389/fimmu.2013.00217. eCollection 2013.
9
Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.来源于分泌特异性抗体的杂交瘤的重组抗原结合分子的构建。
Nat Protoc. 2013 Jun;8(6):1125-48. doi: 10.1038/nprot.2013.057. Epub 2013 May 16.
10
What are biosimilars and are they important?生物类似药是什么,它们重要吗?
Drug Ther Bull. 2013 May;51(5):57-60. doi: 10.1136/dtb.2013.5.0181.